Clever Leaves Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Clever Leaves Holdings's earnings have been declining at an average annual rate of -12.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 21.5% per year.
Anahtar bilgiler
-12.7%
Kazanç büyüme oranı
23.1%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | 21.5% |
| Özkaynak getirisi | -81.7% |
| Net Marj | -113.7% |
| Son Kazanç Güncellemesi | 31 Dec 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Even With A 59% Surge, Cautious Investors Are Not Rewarding Clever Leaves Holdings Inc.'s (NASDAQ:CLVR) Performance Completely
Feb 26
There's No Escaping Clever Leaves Holdings Inc.'s (NASDAQ:CLVR) Muted Revenues
Jun 24Clever Leaves partners with House of Kush for international expansion
Sep 21Clever Leaves reports Q2 results
Aug 11Everyone Says Sell Your Cannabis Stocks! I See It Differently (Podcast Transcript)
Jul 26Clever Leaves exports cannabis to Israel partner Intercure
Jul 18Clever Leaves expands partnership with Cantourage
Jul 11Clever Leaves Remains A Hold As It Ramps Up German Medical Cannabis And Colombian Exports
Jun 10Clever Leaves: New Management Needs To Nail Cannabis Distribution, Not Just Production
Mar 28Clever Leaves Looks Overvalued Based On Fundamentals
Jan 12Clever Leaves CEO Kyle Detwiler - Multi-National Cannabis Wholesaler (Video)
Jul 08Clever Leaves Holdings: A Smart Way To Gain Exposure To Cannabis Market
Jun 27Clever Leaves dispatches commercial flower shipment to Australia through IDT Australia
Jun 21Clever Leaves trades higher on joining Russell Microcap Index
Jun 14Clever Leaves Holdings (CLVR) Presents At 2021 ICR Conference - Slideshow
Jan 13Clever Leaves inks multi-year partnership with Entourage Phytolab
Jan 12Clever Leaves: Not The Ideal Cannabis Position
Jan 06Gelir ve Gider Dağılımı
Clever Leaves Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 23 | 17 | -20 | 20 | 1 |
| 30 Sep 23 | 19 | -51 | 25 | 2 |
| 30 Jun 23 | 18 | -62 | 26 | 2 |
| 31 Mar 23 | 17 | -56 | 28 | 2 |
| 31 Dec 22 | 16 | -38 | 26 | 2 |
| 30 Sep 22 | 16 | -54 | 33 | 2 |
| 30 Jun 22 | 17 | -35 | 37 | 2 |
| 31 Mar 22 | 17 | -46 | 41 | 2 |
| 31 Dec 21 | 15 | -46 | 42 | 2 |
| 30 Sep 21 | 15 | -35 | 38 | 2 |
| 30 Jun 21 | 14 | -42 | 34 | 2 |
| 31 Mar 21 | 13 | -41 | 31 | 1 |
| 31 Dec 20 | 12 | -36 | 31 | 1 |
| 30 Sep 20 | 11 | -39 | 41 | 0 |
| 30 Jun 20 | 11 | -44 | 45 | 0 |
| 31 Mar 20 | 11 | -43 | 43 | 0 |
| 31 Dec 19 | 8 | -40 | 38 | 0 |
Kaliteli Kazançlar: CLVR is currently unprofitable.
Büyüyen Kar Marjı: CLVR is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CLVR is unprofitable, and losses have increased over the past 5 years at a rate of 12.7% per year.
Büyüme Hızlandırma: Unable to compare CLVR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CLVR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: CLVR has a negative Return on Equity (-81.75%), as it is currently unprofitable.